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The most common pathogen in pediatric cystic fibrosis (CF) patients is Staphylococcus aureus, and drug-resistant species are associated with
negative outcomes. Methicillin-resistant Staphylococcus aureus (MRSA) is notoriously hard to treat because many antibiotics are not FDA
approved for children and drug allergies or intolerances can prohibit the use of others. Telavancin is currently indicated for hospital-acquired
pneumonia and ventilator-associated pneumonia caused by MRSA, but it has not been studied in patients with CF or in pediatrics. As a semi-
synthetic derivative of vancomycin, it is unknown if cross-reactivity with telavancin occurs in patients with vancomycin hypersensitivity or
intolerance. In this case series, we describe three adolescent patients with CF and previous intolerance to vancomycin who received telavancin for
bronchopulmonary exacerbations.
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The most common pathogen among pediatric patients with
cystic fibrosis (CF) is Staphylococcus aureus [1]. Unlike the
rates of Pseudomonas aeruginosa, which have been steadily
declining over time, the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) infections increased dramati-
cally in the early 21st century and has remained steady at
approximately 25% over the past five years [1]. While MRSA
prevalence peaks between 18 and 24 years of age, this pathogen
is frequently detected in young children, putting these patients at
risk of decreased lung function and increased mortality
associated with chronic MRSA infection [1,2]. Unfortunately,thor.
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6/j.jcf.2018.08.003pediatric patients with CF have few evidence-based treatment
options, as many anti-MRSA agents are not FDA-approved for
patients less than 18-years of age. Hypersensitivity or intoler-
ance to approved parenteral therapies may also preclude the use
of currently approved agents. Telavancin (Vibativ®), a
lipoglycopeptide antibiotic, is indicated for adults with compli-
cated skin and skin structure infections as well as hospital-
acquired and ventilator-associated bacterial pneumonia caused
by susceptible organisms, including MRSA [3]. As a semi-
synthetic derivative of vancomycin, telavancin poses a potential
risk of hypersensitivity reactions and Redman Syndrome in
patients who previously reacted to vancomycin; however, the
rate of cross-reactivity is not well-established [3]. Telavancin's
utility in patients with CF is not well studied, and a survey
conducted in 2013 did not identify any accredited CF centers
prescribing it commonly for hospitalized pediatric patients with
MRSA infections [2]. The purpose of this case series is to
describe the single center use of telavancin for pulmonary
exacerbations in three adolescent patients with CF who had
documented intolerances or hypersensitivity reactions to van-
comycin. To our knowledge, there are no currently published
case reports documenting the use of telavancin in pediatric
patients or patients with previous intolerance to vancomycin.
2. Case summaries
2.1. Case 1
A 17-year-old female (genotype F508del/E585X) with
previously documented MRSA and Pseudomonas aeruginosa
bronchopneumonia and prior reactions to vancomycin,
ceftaroline, and tigecycline (Table 1) started telavancin 10
mg/kg daily after minimal clinical improvement with oral
linezolid prescribed 9 days prior to admission. For the first dose
of telavancin, she received 10% of the total dose administered
over 1 h with the plan to receive the remaining 90% if tolerated,
as recommended by the allergy and immunology consultants.
However, she developed diffuse hives and pruritus during the
initial infusion that resolved by stopping the infusion andTable 1
Case summaries.
Patient Age Anti-MRSA antibiotic reactions Dose & adminis
Case 1 17 • Vancomycin: oropharyngeal pruritus,
cutaneous eruption, RMS
• Ceftaroline: maculopapular rash, serum
sickness
• Tigecycline: pruritic rash, N/V
10 mg/kg daily (
Test-dose: 10%
Case 2 17 • Vancomycin: RMS, tingling, hives, rash
• Ceftaroline: Delayed cutaneous reaction
10 mg/kg daily (
Given over 60 m
Pretreated with P
50 mg (IP) and 7
Case 3 (1st
course)
12 • Vancomycin: RMS despite administra-
tion as CIV, hives
• Minocycline: Hives
• Ceftaroline: Hives, angioedema of face
and extremities
• Linezolid: Neuropathy
10 mg/kg daily (
Given over 60 m
Pretreated with P
650 mg, PO diph
Case 3 (2nd
course)
13 • Vancomycin: RMS despite administra-
tion as CIV, hives
• Minocycline: Hives









13 • Vancomycin: RMS despite administra-
tion as CIV, hives
• Minocycline: Hives
• Ceftaroline: Hives, angioedema of face
and extremities
• Linezolid: Neuropathy
10 mg/kg daily (
Given over 90 m
Pretreated with P
IP: Inpatient; OP: Outpatient; PO: Oral; IV: Intravenous; CIV: Continuous Intraven
⁎ Experienced itching during test dose that resolved by stopping infusion and giv
⁎⁎ Family noted patient missed final dose due to hives.
⁎⁎⁎ Switched therapy after four doses due to lack of FEV1 response.giving intravenous (IV) diphenhydramine 25 mg. Therefore,
she discontinued telavancin and initiated IV linezolid as an
alternative. Although she also experienced similar symptoms
with the first dose of IV linezolid, she tolerated a similar test-
dose of linezolid and completed approximately 18 days of
therapy before discontinuing due to nausea and vomiting.
2.2. Case 2
A 17-year-old female (genotype F508del/F508del) with
documented MRSA infection and previous reactions to
vancomycin and ceftaroline (Table 1) developed a worsening
cough with post-tussive emesis despite a two-week course of
IV linezolid. She started telavancin 10 mg/kg daily adminis-
tered over 60 min with oral diphenhydramine prior to each
dose. She also started prednisone prior to hospitalization for an
asthma exacerbation and received 30 mg daily that tapered
throughout her antibiotic treatment course. She tolerated six
doses of telavancin in the hospital, with the exception of
experiencing a bad taste in her mouth, and discharged to finish
a three-week course. She experienced chills after her fourth and
fifth doses of outpatient therapy and an extra dose of
clonazepam 0.25 mg, which she already received for anxiety,











450 mg) 0.51 N/A 29 N/A No ⁎
of total dose given over 60 min








(500 mg) 0.45 0.54 97 93 No ⁎⁎
in
O acetaminophen 500-650 mg,
25 mg
540 mg) 0.52 0.53 83 85 No ⁎⁎⁎
in
O/IV diphenhydramine 25 mg
ous Infusion; RMS: Redman Syndrome; N/V: Nausea and vomiting
ing diphenhydramine.
resolved and she completed the full three weeks of therapy
without further adverse effects. Her serum creatinine (SCr)
remained stable throughout therapy (Table 1). Her forced
expiratory volume in 1 s (FEV1) was 55% prior to therapy and
improved to 58% at initial follow-up 11 days after therapy
completed (Table 1). This was documented as her highest FEV1
recorded in the past year.
2.3. Case 3
A 12-year-old female (genotype G551D/F508del) on
ivacaftor with documented MRSA and Pseudomonas
aeruginosa infections, and previous reactions to vancomycin,
minocycline, ceftaroline, and linezolid (Table 1) received three
courses of telavancin over a 10-month period. The first course
was initiated during a hospitalization for a CF pulmonary
exacerbation. Telavancin 10 mg/kg daily was administered
over 60 min with oral acetaminophen and diphenhydramine
given prior to doses. She also started oral ciprofloxacin and
inhaled tobramycin to treat Pseudomonas aeruginosa at that
time. She had mild facial flushing after the first dose of
telavancin, but tolerated five doses administered in the hospital
and her cough improved. She discharged and completed a 16-
day course. Her SCr remained stable and FEV1 increased from
96% of predicted on day of admission to 102% of predicted 1
week after finishing therapy (Table 1).
During a subsequent hospitalization five months later, she
started a second course of telavancin at a dose rounded to an
even vial quantity of 8.7 mg/kg daily. Her cultures were only
positive for MRSA at this time. She received two doses while
inpatient and was discharged to finish a two week course in the
outpatient setting. Her family noted she experienced hives at
the end of therapy causing her to miss her final dose, though
this was not confirmed by a medical provider. Her SCr
remained stable throughout therapy, but FEV1 declined from
97% predicted prior to therapy to 93% predicted on day of
therapy completion (Table 1). Cultures obtained at that time
were newly positive for Aspergillus fumigatus.
A third course of telavancin in addition to oral voriconazole
occurred during a hospitalization four months later. She
received telavancin 10 mg/kg daily and tolerated four doses
despite pruritus without hives before switching to tigecycline
due to an inadequate response in lung function. Her renal
function remained stable while receiving telavancin (Table 1).
3. Discussion
Telavancin, a lipoglycopeptide antibiotic, is an effective
agent against MRSA in the adult population, but has not beenstudied in pediatrics yet. An initial phase III trial of telavancin
excluded patients with CF, so efficacy in this population
requires further exploration [4]. At our center, three adolescent
patients with CF and documented intolerance to vancomycin
received telavancin on five different occasions. Two patients
tolerated full courses of telavancin at doses of 10 mg/kg daily
administered over 60 min and safely received telavancin in the
outpatient setting as well. FEV1 improved in two cases of
telavancin use. Patients should be monitored for cross-
reactivity as one patient with a previous IgE-mediated reaction
to vancomycin did not tolerate a test dose of telavancin.
Telavancin can cause nephrotoxicity, but each patient's renal
function remained stable during treatment [4]. Of note, no
patients received concomitant nephrotoxic antibiotics, such as
aminoglycosides, which are associated with exacerbating the
nephrotoxicity of vancomycin [5]. Lastly, all patients were at
least 12 years of age and weighed at least 45 kg. It is unknown
if the dosing strategies used would be safe in younger or
smaller children, but a trial evaluating the pharmacokinetics of
telavancin in children ages 3 months to 17 years is underway
(NCT02013141). Our experience suggests that previous
intolerance, such as Redman Syndrome, to vancomycin should
not prohibit a trial of telavancin with premedication and that a
dose of 10 mg/kg daily administered over at least 60 min
appears safe for patients weighing over 45 kg. However,
patients with an IgE-mediated allergy to vancomycin may be
at a higher risk of cross-reactivity.
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